SINGAPORE-- As soon as the Delhi High Court revived Gilead Sciences' patent hopes for Sovaldi, a new actor has come on the scene: Sankalp Rehabilitation Trust, which has joined three other plaintiffs in opposing the new patent.
Dr. Reddy's Laboratories is weighing a shift away from its Srikakulam facility in southern India where some of its key active pharmaceutical ingredients are produced and which is under an FDA investigation.
A Pfizer plant in Ireland that was slated to close last year is still running strong, as sales of blockbuster cholesterol drug Lipitor remain vibrant in some parts of the world three years after losing its U.S. patent.
India has long been a major player in the development and manufacturing of treatments, but more and more drugmakers are outsourcing the monitoring of on-the-market drugs to vendors in the country.
Mylan will pay $750 million in cash to buy the women's healthcare businesses from India's Famy Care, placing it as the top seller of contraceptives in emerging markets.
Who knew that China FDA's planned lifting of a ban on online drug sales meant the global pharmaceutical industry could become a subject of a Chinese version of palace intrigue?
SINGAPORE-- A change in leadership at the China Drug and Food Administration was announced on the Communist Party website last week: Bi Jingquan, who has more than 20 years of experience in pricing and management, will take over from Zhang Yong as CFDA minister.
Ranbaxy Laboratories may soon be selling its generic minocycline antibacterial drug to Torrent Pharmaceuticals as a condition for U.S. approval for its merger with Sun Pharmaceuticals.
Johnson & Johnson is partnering with Insuline Medical to register and distribute the Israeli company's InsuPad for promoting optimal absorption of insulin in diabetics by warming their injection site.
India's National Pharmaceutical Pricing Authority has told drugmakers that failure to hand in drug price and sales data by next week is not an option.